PEspeaks

Dec 11, 2017
Pharmaceutical Executive
In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.
Dec 10, 2017
Pharmaceutical Executive
New action plan urges tighter alignment of public health policy with the development of targeted therapies.
Dec 06, 2017
Pharmaceutical Executive
This Q&A with Lumicell CEO Kelly Londy discusses new drug-device technologies in development for a range of cancers, beginning with breast cancer in the most advanced clinical studies.
Dec 06, 2017
Bagrat Lalayan presents an overview of osteoporosis treatment market and offers vision for future business strategies.
Dec 05, 2017
Pharmaceutical Executive
Innovation by itself won't solve the complex multichannel challenges pharmas face. Jeff Greene reports.
Nov 30, 2017
Experts slam drug prices and endorse government price negotiations and curbs on drug advertising.
Nov 22, 2017
Jill Wechsler discusses the hot topic of how FDA should oversee combination products that incorporate a digital health component.
Nov 16, 2017
Pharmaceutical Executive
is spectacular science enough to guarantee success for new medicines?
Nov 16, 2017
Pharmaceutical Executive
If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.
Nov 16, 2017
John Sattler offers some tips on engaging executive and professional recruiters.
native1_300x100
lorem ipsum